http://chineseinput.net/에서 pinyin(병음)방식으로 중국어를 변환할 수 있습니다.
변환된 중국어를 복사하여 사용하시면 됩니다.
- 中文 을 입력하시려면 zhongwen을 입력하시고 space를누르시면됩니다.
- 北京 을 입력하시려면 beijing을 입력하시고 space를 누르시면 됩니다.
RISS 인기검색어
- 검색키워드
- 저자 : 강승수(Seung Su Kang) (검색결과 5 건)
- 무료
- 기관 내 무료
- 유료
-
강승수(Kang, Seung Su),서유석(Seo, You Seok) 한국주거환경학회 2016 주거환경(한국주거환경학회논문집) Vol.14 No.4
Innovation City was Urban Development Method of New Concept and developed leading by Korean Government. It"s main purpose was to solve the overpopulated problems in Korean capital area, to upgrade national competitive power and achieve balanced development between regions in Korea. As Innovation City"s plan and site development made by politic needs was constructed in short time, it has been developing without adequate considering of regional development demand and characteristics, even more harmony and relationship with existing urban spatial structure. Accordingly, it was resulted in serious urban problem like as population emptiness and deterioration in existing downtown. Gyeongnam Innovation City is the biggest urban development project in respect of it"s scale and urban function, residential environment etc. in Jinju, and guess to affect seriously existing downtown as it"s construction proceeds. Therefore, this study aims to analyse effects of existing urban spatial structure in the course of development of Gyeongnam Innovation City, and to classify positive and negative factors affecting existing downtown of it, finally, to be harmony construction between existing downtown and Gyeongnam Innovation City. As a result of this study, development of Gyeongnam Innovation City was affected negatively to existing downtown in Jinju, especially, commercial and residential area. Real estate price has been declining in commercial area and emptiness in residential area was occurred in existing downtown. This is serious problem in considering that Gyeongnam Innovation City is not developed completely.
-
-
만성 C 형 간염 환자에서 인터페론치료에 의한 갑상선질환의 발생
김민대(Min Dae Kim),전익수(Ik Soo jeon),강승수(Seung Su Kang),엄재섭(Jae Sup Eum),손호성(Ho Seung Son),박현용(Hyung Lyong Park),윤병철(Byung Cheol Yun),이상욱(Sang Uk Lee),한병훈(Byung Hoon Han) 대한소화기학회 2001 대한소화기학회지 Vol.37 No.6
Background/Aims: It has been suggested that hepatitis C virus is associated with the autoimmune disease and interferon also induces hepatic and non-hepatic autoimmune reaction. We conducted this study to assess the effect of interferon-alpha (INF-α) on the induction of thyroid autoantibodies and clinical thyroid disease and to know whether the thyroid autoantibodies affect the IFN-α efficacy in patients with chronic hepatitis C. Methods: Twenty-nine patients with chronic hepatitis C were enrolled. Anti-thyroglobulin antibody (ATA), anti-microsomal antibody (AMsA), thyroid stimulating hormone and free thyroxine were measured before, during, and after IFN-α therapy. Results: Two of the 29 patients (6.5%) were positive for ATA and AMsA before IFN-α therapy. Of these two patients, one patient was a woman, who showed hyperthyroidism druing IFN-α therapy. Of the 27 patients who had been negative for ATA and AMsA, one female patient became ATA positive with the development of hyperthyroidism, and 3 male patients became AMsA positive during IFN-α therapy. There was no difference in the efficacy of INF-α therapy between the thyroid autoantibody positive and negative groups. Conclusions: IFN-α therapy induced thyroid disease with high prevalence in the patients with chronic hepatis C. Thus, thyroid status should be checked even in patients without thyroid autoantibodies, especially in woman. Antithyroid autoantibodies seem unlikely to affect the efficacy of IFN-α therapy. (Korean J Gastroenterol 2001;37:436-442)
-
김길수,전익수,신성훈,김민대,강승수,권성일,옥철호,조현명,장태원,정만홍 고신대학교 의학부 2001 高神大學校 醫學部 論文集 Vol.16 No.1
Background Multidrug-resistant tuberculosis (MDRTB) is defined as the reduction in susceptibility of Mycobacterium tuberculosis to Isoniazid and Rifampicin with or without resistance to additional drugs. The development of MDRTB is a big problem not only to the patients but also to the society given with its lower cure rate. The purpose of this study is to investigate the prevalence and the clinical features of MDRTB at university hospital and to establish the proper therapeutic plan. Method The incidence of MDRTB among 161 patients diagnosed as pulmonary tuberculosis by the AFB culture between January 1997 and June 2000, and the relationship of MDRTB with the history of previous therapy, associated diseases, bronchial involvement, and the consequence of treatment were studied retrospectively. Results Fortyeight (29.8%) patients were resistant to at least one drug and 27 (16.8%) patients suffered from MDRTB. Among the MDRTB patients, 22 had the previous history of therapy. More than 30 percent of all the patients had associated diseases, such diabetes mellitus, malignancy, chronic liver disease, systemic erythematous lupus or psychosis. Endobronchial lesions suggesting bronchial involvement of tuberculosis were found in 37 (35%) patients. Out of the 16 patients eligible for the efficacy of treatment among 27 MDRTB patients, nine (56.3%) patients were treated successfully but seven (43.8%) were failed. Conclusion Prevalence of MDRTB was high especially in patients with previous therapy history and the results of treatment was modest in this study. It is imperative to prevent the emergence of drug resistance by the proper delivery of chemotherapy and the development of new drugs.
-
Cerivastatin과 Cyclosporine을 병용 투약한 신이식 환자에서의 횡문근융해증 1예
신성훈,김민대,강승수,김찬욱,이지영,엄재섭,권성일,김길수,정연순,임학 고신대학교 의학부 2002 高神大學校 醫學部 論文集 Vol.17 No.1
Cerivastatin, a kind of statins, is a recently used lipid-lowering drug. which inhibits of hydroxymethylglutarate coenzyme A (HMG-CoA) reductase. The serum concentrations of statins in healthy volunteers are increased by the simultaneous administration of cyclosporine, itraconazole, as well as erythromycin and verapamil and increased risk of myalgia and rhabdomyolysis has been reported after concomitant use of HMG-CoA reductase inhibitors with these drugs. A 57-year-old female kidney transplant recipient admitted because of a dark urine, myalgia and weakness of extremities. Six weeks before admission, the patient has taken cerivastatin 0.3mg daily. Cyclosporine, prednisolone and mycophenolate mofetil were maintained for recent two years. Initial laboratory data showed serum creatinine 1.1mg/dl, AST 235 IU/L, LDH 2,465 IU/L, CPK 1600 IU/L, myoglobin >3,000 ng/ml and cyclosporine 288ng/ml (TDX). Medication of cerivastatin was discontinued, and the patient recovered rapidly with supportive therapy. After eighteen weeks of cerivastatin withdrawal. the drug was represcribed to control the increased lipid levels. The patient showed the same clinical manifestations suggesting rhabdomyolysis following eight weeks of cerivastatin administration. We report a case of rhabdomyolysis associated with cerivastatin and cyclosporine combination therapy in a kidney transplant recipient.
KCI
스콜라연관 검색어 추천
이 검색어로 많이 본 자료
활용도 높은 자료
